OTCM
NUMD
Market cap3mUSD
Jul 11, Last price
0.04USD
1D
-0.24%
1Q
-53.33%
Jan 2017
-83.20%
IPO
-95.80%
Name
Nu-Med Plus Inc
Chart & Performance
Profile
Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. It develops a hospital nitric oxide delivery system, a clinical nitric oxide delivery system, a mobile rechargeable device to deliver nitric oxide gas, and a nitric oxide system that can be used for research applications. The company serves hospitals, health systems, and the medical community. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 63 | 133 | 193 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (63) | (133) | (193) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (68) | 1,000 | ||||||||
Tax Rate | ||||||||||
NOPAT | 5 | (133) | (194) | |||||||
Net income | (68) -45.55% | (126) -4.30% | (131) -84.20% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 100 | 100 | ||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | (2,199) | (2,066) | ||||||||
Net debt | (2) | 93 | 27 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (4) | (66) | (38) | |||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | 100 | |||||||||
FCF | 174 | (87) | (318) | |||||||
Balance | ||||||||||
Cash | 2 | 7 | 73 | |||||||
Long term investments | ||||||||||
Excess cash | 2 | 7 | 73 | |||||||
Stockholders' equity | (9,810) | (9,741) | (9,618) | |||||||
Invested Capital | 9,595 | 7,496 | 7,582 | |||||||
ROIC | 0.06% | |||||||||
ROCE | 29.30% | 285.40% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 83,548 | 81,674 | 79,951 | |||||||
Price | 0.02 -62.05% | 0.04 145.15% | 0.02 -52.86% | |||||||
Market cap | 1,282 -61.18% | 3,304 150.43% | 1,319 -48.63% | |||||||
EV | 1,280 | 3,397 | 1,346 | |||||||
EBITDA | (63) | (133) | (182) | |||||||
EV/EBITDA | ||||||||||
Interest | 5 | 5 | 1,000 | |||||||
Interest/NOPBT |